A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00109278

Enrollment

1100

Registered

2005-04-26

Start date

2004-10-31

Completion date

2005-05-31

Last updated

2017-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Measles

Keywords

Prevention of Measles

Brief summary

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Detailed description

The duration of treatment is 6 weeks.

Interventions

BIOLOGICALV205C, measles, mumps, and rubella virus vaccine live

BIOLOGICALComparator: Measles, Mumps, and Rubella Virus Vaccine Live

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

12 Months to 18 Months

Healthy volunteers

Yes

Inclusion criteria

* Healthy children 12 to 18 months of age.

Exclusion criteria

* Previous receipt of measles, mumps, rubella and/or varicella vaccine. * Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster. * Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy. * History of seizures (convulsions) * Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin. * A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F \[37.5° C\]).

Design outcomes

Primary

Measure	Time frame
Antibody response rate to measles at 6 weeks postvaccination	—

Secondary

Measure	Time frame
Geometric mean titers to measles by ELISA at 6 weeks postvaccination	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026